Literature DB >> 27614971

Roles of organic anion transporters (OATs) in renal proximal tubules and their localization.

Naoyuki Otani1, Motoshi Ouchi1, Keitaro Hayashi1, Promsuk Jutabha1, Naohiko Anzai2,3.   

Abstract

Organic anions (OAs) are secreted in renal proximal tubules in two steps. In the first step, OAs are transported from the blood through basolateral membranes into proximal tubular cells. The prototypical substrate for renal organic anion transport systems, para-aminohippurate (PAH), is transported across basolateral membranes of proximal tubular cells via OAT1 (SLC22A6) and OAT3 (SLC22A8) against an electrochemical gradient in exchange for intracellular dicarboxylates. In the second step, OAs exit into urine through apical membranes of proximal tubules. This step is thought to be performed by multidrug efflux transporters and a voltage-driven organic anion transporter. However, the molecular nature and precise functional properties of these efflux systems are largely unknown. Recently, we characterized an orphan transporter known as human type I sodium-phosphate transporter 4, hNPT4 (SLC17A3), using the Xenopus oocyte expression system. hNPT4 acts as a voltage-driven efflux transporter ("human OATv1") for several OAs such as PAH, estrone sulfate, diuretic drugs, and urate. Here, we describe a model for an OA secretory pathway in renal tubular cells in which OAs exit cells and enter the tubular lumen via hOATv1 (hNPT4). Additionally, hOATv1 functions as a common renal secretory pathway for both urate and drugs, indicating that hOATv1 may be a leak pathway for excess urate that is reabsorbed via apical URAT1 to control the intracellular urate levels. Therefore, we propose a molecular mechanism for the induction of hyperuricemia by diuretics: the diuretics enter proximal tubular cells via basolateral OAT1 and/or OAT3 and may then interfere with the NPT4-mediated apical urate efflux in the renal proximal tubule.

Entities:  

Keywords:  Drugs; Organic anion; Transporter; Uric acid

Mesh:

Substances:

Year:  2016        PMID: 27614971     DOI: 10.1007/s12565-016-0369-3

Source DB:  PubMed          Journal:  Anat Sci Int        ISSN: 1447-073X            Impact factor:   1.741


  13 in total

1.  Guided tissue organization and disease modeling in a kidney tubule array.

Authors:  Balajikarthick Subramanian; Oguzhan Kaya; Martin R Pollak; Gang Yao; Jing Zhou
Journal:  Biomaterials       Date:  2018-08-10       Impact factor: 12.479

Review 2.  An Integrated View of Aristolochic Acid Nephropathy: Update of the Literature.

Authors:  Inès Jadot; Anne-Emilie Declèves; Joëlle Nortier; Nathalie Caron
Journal:  Int J Mol Sci       Date:  2017-01-29       Impact factor: 5.923

3.  Hypouricemic Effect of 2,5-Dihydroxyacetophenone, a Computational Screened Bioactive Compound from Ganoderma applanatum, on Hyperuricemic Mice.

Authors:  Danling Liang; Tianqiao Yong; Shaodan Chen; Yizhen Xie; Diling Chen; Xinxin Zhou; Dan Li; Muxia Li; Lu Su; Dan Zuo
Journal:  Int J Mol Sci       Date:  2018-05-07       Impact factor: 5.923

4.  Treatment with a PPAR-γ Agonist Protects Against Hyperuricemic Nephropathy in a Rat Model.

Authors:  Xin Wang; Jin Deng; Chongxiang Xiong; Haishan Chen; Qin Zhou; Yue Xia; Xiaofei Shao; Hequn Zou
Journal:  Drug Des Devel Ther       Date:  2020-06-08       Impact factor: 4.162

5.  Pharmacologic Targeting of BET Proteins Attenuates Hyperuricemic Nephropathy in Rats.

Authors:  Chongxiang Xiong; Jin Deng; Xin Wang; Xiaofei Shao; Qin Zhou; Hequn Zou; Shougang Zhuang
Journal:  Front Pharmacol       Date:  2021-02-16       Impact factor: 5.810

Review 6.  Modulation of Urate Transport by Drugs.

Authors:  Péter Tátrai; Franciska Erdő; Gabriella Dörnyei; Péter Krajcsi
Journal:  Pharmaceutics       Date:  2021-06-17       Impact factor: 6.321

Review 7.  Recent advances on uric acid transporters.

Authors:  Liuqing Xu; Yingfeng Shi; Shougang Zhuang; Na Liu
Journal:  Oncotarget       Date:  2017-08-10

Review 8.  Physiology of Hyperuricemia and Urate-Lowering Treatments.

Authors:  Caroline L Benn; Pinky Dua; Rachel Gurrell; Peter Loudon; Andrew Pike; R Ian Storer; Ciara Vangjeli
Journal:  Front Med (Lausanne)       Date:  2018-05-31

9.  Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study.

Authors:  Youssef Saeed Alghamdi; Mohamed Mohamed Soliman; Mohamed Abdo Nassan
Journal:  BMC Pharmacol Toxicol       Date:  2020-02-10       Impact factor: 2.483

10.  Effect and Mechanism of ShiZhiFang on Uric Acid Metabolism in Hyperuricemic Rats.

Authors:  Yansheng Wu; Yixing Wang; Jiaoying Ou; Qiang Wan; Liqiang Shi; Yingqiao Li; Fei He; Huiling Wang; Liqun He; Jiandong Gao
Journal:  Evid Based Complement Alternat Med       Date:  2018-06-25       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.